Quest Diagnostics price target raised to $177 from $174 at Mizuho

Mizuho analyst Ann Hynes raised the firm’s price target on Quest Diagnostics (DGX) to $177 from $174 and keeps an Outperform rating on the shares in conjunction with publishing the firm’s 2025 outlook note for managed care, acute care, behavioral health, clinical labs, clinical research organizations, physician services, post-acute care, retail pharmacies, and surgery centers. The firm believes the two main themes for all of those subsectors is whether the demand environment is durable and what, if any, is the regulatory risk/benefit from the new administration in Washington, the analyst tells investors.